Prevalence and immediate adverse birth outcomes following augmentation of labor with oxytocin at Mbarara Regional Referral Hospital, Southwestern Uganda. A cross-sectional study.
DOI:
https://doi.org/10.51168/de0ww460Keywords:
Oxytocin augmentation, adverse birth outcomes, labor augmentation, Apgar score, Mbarara Regional Referral HospitalAbstract
Background:
Augmentation of labor using oxytocin is widely practiced to manage inadequate uterine contractions and prevent prolonged labor. However, its use has been associated with adverse maternal and perinatal outcomes, including uterine hyperstimulation, postpartum hemorrhage, fetal distress, and increased operative deliveries. This study assessed the prevalence and immediate adverse birth outcomes among women undergoing augmentation of labor at a tertiary hospital in Southwestern Uganda.
Methodology:
A hospital-based cross-sectional study was conducted from December 2024 to April 2025 among 210 women who delivered following oxytocin augmentation at Mbarara Regional Referral Hospital. Data were collected using a pre-tested questionnaire and clinical chart review. Immediate adverse birth outcomes were defined as maternal and/or perinatal complications occurring within 24 hours of delivery. Data were analyzed using Stata version 17 to determine prevalence and associated characteristics.
Results:
The prevalence of immediate adverse birth outcomes was 22.4% (95% CI: 17.2–28.6%). Adverse maternal outcomes alone occurred in 11.0% of participants, perinatal outcomes alone in 7.1%, while 4.3% experienced both. The most common maternal outcomes were caesarean section (6.2%) and postpartum hemorrhage (5.2%). Among perinatal outcomes, low Apgar score (<7 at 5 minutes) and neonatal intensive care unit admission were most frequent (8.1% each). Referral status and marital status showed significant associations with adverse outcomes.
Conclusion:
The prevalence of immediate adverse birth outcomes following oxytocin augmentation is high, highlighting a significant obstetric concern. Both maternal and neonatal complications remain common in this setting.
Recommendation:
Strengthening adherence to labor monitoring protocols, particularly the use of the WHO labor care guide, and careful selection and monitoring of women undergoing oxytocin augmentation are essential to reduce adverse birth outcomes.
References
1. World Health Organization (WHO). (2014). WHO recommendations for augmentation of labour. Geneva: WHO.
2. World Health Organization (WHO). (2018). WHO recommendations: Intrapartum care for a positive childbirth experience. Geneva: WHO.
3. American College of Obstetricians and Gynecologists (ACOG). (2019). Approaches to limit intervention during labor and birth. Obstetrics & Gynecology, 133(2), e164–e173.
4. Uvnäs-Moberg, K. (2024). Oxytocin: The biological guide to motherhood and bonding. Acta Physiologica, 230(2), e13567. https://doi.org/10.1097/AOG.0000000000003074
5. Phaneuf, S., Rodríguez Liñares, B., TambyRaja, R. L., MacKenzie, I. Z., & López Bernal, A. (1998). Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour. Journal of Reproduction and Fertility, 112(2), 199–206.
6. Grotegut, C. A., Feng, L., Mao, L., Heine, R. P., Murtha, A. P., & Rockman, H. A. (2011). The influence of labor duration on uterine atony and postpartum hemorrhage. American Journal of Obstetrics and Gynecology, 205(5), 1–6.
7. Bugg, G. J., Siddiqui, F., & Thornton, J. G. (2006). Oxytocin versus no treatment or delayed treatment for slow progress in the first stage of spontaneous labour. Cochrane Database of Systematic Reviews, (2), CD007123.
8. Hidalgo-Lopezosa, P., Hidalgo-Maestre, M., & Rodríguez-Borrego, M. A. (2016). Labor stimulation with oxytocin: Effects on obstetrical and neonatal outcomes. Revista Latino-Americana de Enfermagem, 24, e2744. https://doi.org/10.1590/1518-8345.0765.2744
9. Espada-Trespalacios, X., Ojeda, F., & González, R. (2021). Oxytocin use and perinatal outcomes in labor: A multicenter study. BMC Pregnancy and Childbirth, 21, 345.
10. Bernitz, S., Øian, P., Rolland, R., & Blix, E. (2014). Oxytocin augmentation and adverse birth outcomes. Acta Obstetricia et Gynecologica Scandinavica, 93(7), 715–723.
11. Kjaergaard, H., Olsen, J., Ottesen, B., & Dykes, A. K. (2009). Obstetric outcomes following oxytocin augmentation. Birth, 36(1), 36–43. https://doi.org/10.1111/j.1523-536X.2008.00294.x
12. Wojnar, D. M., Perkins, M., & Byrd, M. E. (2014). Oxytocin augmentation and neonatal outcomes in the United States. Journal of Midwifery & Women’s Health, 59(2), 151–157.
13. Litorp, H., Kidanto, H. L., Nystrom, L., & Darj, E. (2021). Oxytocin use in low-resource settings and associated perinatal outcomes. BMC Pregnancy and Childbirth, 21, 112.
14. Uganda Bureau of Statistics (UBOS) & ICF. (2022). Uganda Demographic and Health Survey 2022. Kampala, Uganda, and Rockville, Maryland, USA.
15. Ministry of Health, Uganda. (2020). Annual Health Sector Performance Report. Kampala: Ministry of Health.
16. Chelmow, D., & Laros, R. K. (1992). The impact of oxytocin augmentation on labor outcomes. Obstetrics & Gynecology, 80(5), 741–745.
17. Selin, L., Almström, E., Wallin, G., & Berg, M. (2009). Use of oxytocin for labor augmentation and associated outcomes. Acta Obstetricia et Gynecologica Scandinavica, 88(7), 771–778.
18. Svärdby, K., Nordström, L., & Sellström, E. (2007). Instrumental delivery and oxytocin augmentation. Acta Obstetricia et Gynecologica Scandinavica, 86(7), 803–808.
19. Mbarara Regional Referral Hospital (MRRH). (2023). Annual Hospital Report. Mbarara, Uganda.
20. Kish, L. (1965). Survey Sampling. New York: John Wiley & Sons.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dr. Dickens Mugumya, Dr. Onesmus Byamukam, Assoc. Prof. Rogers Kajabwangu, Musa Kayondo, Leevan Tibaijuka, Joseph Ngonzi, Daniel Begumana, Mohamed Bashir, Edwin Semambo, Julius Businge, Paul Kato Kalyebara (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
